CytoSorbents Corporation (CTSO)

[cars100cars]

Bio, thanks for your analysis. Your last paragraph seems to get at the heart of the issue for both Spectral and CTSO in the U.S. and Canadian markets. The issue is all about how the FDA determines approval in this category. It is abundantly clear that CytoSorb reduces severe destructive inflammation. But, so far, this has NOT seemed important to the FDA. Then again, for a growing number of docs and hospitals in 40 countries where the FDA doesn't matter, this critical treatment option does matter for docs to regain control of gravely ill patients across a wide section of indications. As the result, CytoSorb continues to grow revenues quarter after quarter. CytoSorb may soon exceed 30,000 treatments. The rate of treatments is accelerating. As for Spectral, they have a completely different plan to reach the market. I wish you luck relying on the FDA. I'd rather be in CTSO.